Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events
- 29 January 2005
- Vol. 23 (25) , 3256-3263
- https://doi.org/10.1016/j.vaccine.2005.01.089
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX®Vaccine, 2004
- Effects of yellow fever vaccinationThe Lancet, 2001
- Effects of yellow fever vaccinationThe Lancet, 2001
- Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever VaccinationEmerging Infectious Diseases, 2001
- Effects of yellow fever vaccinationThe Lancet, 2001
- Hepatitis and death following vaccination with 17D-204 yellow fever vaccineThe Lancet, 2001
- Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four casesThe Lancet, 2001
- Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two casesThe Lancet, 2001
- Anaphylaxis from yellow fever vaccineJournal of Allergy and Clinical Immunology, 1999
- The vaccine adverse event reporting system (VAERS)Vaccine, 1994